HC Wainwright Boosts Earnings Estimates for OPKO Health

OPKO Health, Inc. (NASDAQ:OPK) – Analysts at HC Wainwright lifted their FY2026 earnings estimates for shares of OPKO Health in a research note issued to investors on Wednesday, April 29th. HC Wainwright analyst Y. Chen now forecasts that the biotechnology company will post earnings per share of ($0.30) for the year, up from their previous estimate of ($0.31). The consensus estimate for OPKO Health’s current full-year earnings is ($0.27) per share. HC Wainwright also issued estimates for OPKO Health’s Q4 2026 earnings at ($0.07) EPS.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings data on Tuesday, April 28th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). OPKO Health had a negative net margin of 36.63% and a negative return on equity of 16.78%. The company had revenue of $124.20 million during the quarter, compared to the consensus estimate of $130.51 million. During the same period last year, the firm earned ($0.10) EPS. OPKO Health’s revenue for the quarter was down 17.1% on a year-over-year basis.

OPK has been the subject of several other reports. Wall Street Zen downgraded shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Barrington Research downgraded shares of OPKO Health from an “outperform” rating to a “market perform” rating in a report on Wednesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $1.55.

OPKO Health Stock Up 1.4%

Shares of NASDAQ:OPK opened at $1.13 on Friday. The firm has a fifty day moving average price of $1.18 and a two-hundred day moving average price of $1.28. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.61 and a quick ratio of 3.52. OPKO Health has a one year low of $0.98 and a one year high of $1.60. The company has a market cap of $849.48 million, a price-to-earnings ratio of -4.17 and a beta of 1.49.

Institutional Trading of OPKO Health

A number of hedge funds have recently made changes to their positions in the stock. Comerica Bank lifted its holdings in shares of OPKO Health by 7.1% during the 4th quarter. Comerica Bank now owns 120,000 shares of the biotechnology company’s stock worth $151,000 after acquiring an additional 8,000 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of OPKO Health by 4.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 198,148 shares of the biotechnology company’s stock worth $262,000 after acquiring an additional 8,954 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of OPKO Health by 11.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 138,643 shares of the biotechnology company’s stock worth $183,000 after acquiring an additional 13,912 shares during the last quarter. Intech Investment Management LLC lifted its holdings in shares of OPKO Health by 11.4% during the 4th quarter. Intech Investment Management LLC now owns 159,652 shares of the biotechnology company’s stock worth $201,000 after acquiring an additional 16,329 shares during the last quarter. Finally, Caprock Group LLC bought a new stake in shares of OPKO Health during the 3rd quarter worth $26,000. 64.63% of the stock is owned by institutional investors.

Trending Headlines about OPKO Health

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: OPKO expanded its agreement with Nicoya to support commercialization of RAYALDEE® in Greater China and received a 15% equity stake in Nicoya, strengthening OPKO’s potential upside from international rollout and aligning partner commitment ahead of expected approvals in 2027. OPKO Nicoya Agreement
• Positive Sentiment: BioReference (an OPKO subsidiary) launched BioReference Direct™, a consumer‑facing digital testing platform that could broaden access and help stabilize/expand diagnostics revenue over time. BioReference Direct Launch
• Positive Sentiment: HC Wainwright nudged up EPS forecasts slightly for Q4 2026 and FY2026 (and published steady quarterly assumptions for 2027), trimming projected losses a touch — a small but constructive analyst revision that can support sentiment for a beaten‑up stock.
• Neutral Sentiment: Q1 results: EPS came in line with estimates and showed product sales gains, but total revenue fell ~25.7% year‑over‑year (smaller BioReference diagnostics base), leaving mixed signals on near‑term top‑line momentum. Q1 Earnings Coverage
• Negative Sentiment: Barrington Research downgraded OPKO from “outperform” to “market perform,” a change that can pressure the stock by reducing bullish analyst support and dealer enthusiasm. Barrington Downgrade

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.